Our study further elucidates the potential role of Th9 cells in anti-PD-1 mediated anti-cancer immunity, suggesting that further studies investigating the biological effects of Th9 in Nivolumab mediated anti-cancer immune responses could potentially lead to a new combination therapy that targets Th9 cells. The gene discussed is PDCD1; the disease is cancer.